Drug maker STADA says problems in Serbia weigh down on Q3 result.s.

By bne IntelliNews September 30, 2010
German drug maker STADA Arzneimittel AG said its Q3 earnings are burdened by problems in Serbia, where the customers of its subsidiary HemofarmVrsac cannot pay their debts, STADA said in a statement posted on its website. As a result of the liquidity problems of Serbian wholesalers, STADA said it expects one-off earnings burden worth about EUR 29.5mn before taxes in Q3. However, STADA'a management still considers the full-year target results achievable.

Related Articles

Serbia's external debt up 4.7% y/y to EUR 25.4bn at end-Feb 2013.

Serbia's foreign debt rose an annual 4.7% y/y to EUR 25.4bn at end-February after climbing 6.6% on the year in January, central bank data showed. In monthly terms, however, the external ... more

Vip Mobile Serbia signs five-year managed services deal with Ericsson.

Swedish company Ericsson said it has signed a five-year managed services contract with Vip Mobile - the Serbian arm of Telekom Austria Group. The agreement includes field maintenance services for ... more

Telenor and Societe General possible buyers of Serbia's KBC Banka - report.

Norwegian telecommunications firm Telenor and France's Societe General are seen as possible buyers of the Serbian unit of Belgium's KBC Group, which has been on sale for several years now, a ... more

Notice: Undefined index: subject_id in /var/www/html/application/controllers/IndexController.php on line 335
Dismiss